Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer

International Journal of Clinical Oncology

Volumn 7, Issue 3, 2002, Pages 171-176

  Ohno, Tsuyoshi ^a   Kawano, Katsunori ^a   Sasaki, Atsushi ^a   Aramaki, Masanori ^a   Tahara, Kouichirou ^a   Etoh, Tsuyoshi ^a   Kitano, Seigo ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

AC 7700; Blood flow; Combretastatin A 4; Hepatocellular carcinoma; In vivo fluorescence microscopy; Tubulin binding agent

Indexed keywords

COMBRETASTATIN A4; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; SERINE; TUBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; LIVER CELL CARCINOMA; MALE; MICROTUBULE ASSEMBLY; NECROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; LIVER TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SURVIVAL RATE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMAL; ANTINEOPLASTIC AGENTS; COMPARATIVE STUDY; DISEASE MODELS, ANIMAL; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RATS; SERINE; SURVIVAL RATE; TUBULIN; TUMOR CELLS, CULTURED; ANIMALS;

EID: 0035985910     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470200025     Document Type: Article

References (33)

1. Changing incidence of hepatocellular carcinoma in Japan
2. Increase in primary liver cancer in the UK, 1979-1994
3. Rising incidence of hepatocellular carcinoma in the United States
4. The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: Improved survival of surgically resected patients, 1985-1996
5. A comparative study of hepatic resection and transcatheter arterial embolization for the treatment of primary hepatocellular carcinoma
6. Predictive factors for postoperative recurrence of hepatocellular carcinoma
7. Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection
8. The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy
9. Microwave coagulonecrotic therapy for hepatocellular carcinoma
10. Clinical trials in primary hepatocellular carcinoma: Current status and future directions
11. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution
12. Vascular reaction of normal and malignant tissues in vivo VI. The role of hypotension in the action of components of podophyllin on transplantable sarcomas
13. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor
14. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies
15. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin
16. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
17. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
18. Novel combretastatin analogues effective against murine solid tumors: Design and structure-activity relationships
19. Syntheses and antitumor activity of cis-restricted combretastatins: 5-Membered heterocyclic analogues
20. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors
21. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy
22. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700
23. Major hepatic resection may suppress the growth of tumors remaining in the residual liver
24. Intra-arterial chemoembolization in patients with hepatocellular carcinoma
25. The interaction with tubulin of a series of stilbenes based on combretastatin A-4
26. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug
27. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
28. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
29. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
30. Hepatobiliary surgery
31. Intrahepatic cholangiocarcinoma
32. Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4
33. A phase I pharmacokinetic study of single dose intravenous combretastatin A4 prodrug in patients with advanced cancer